From: Barriers and challenges in integration of anthroposophic medicine in supportive breast cancer care
Characteristic | Total cohort N = 341, n (%) | AM group N = 56, n (%) | Non-AM group N = 285, n (%) | P value |
---|---|---|---|---|
Age [Mean in years ± SD (median)] | 62.26 ± 12.58 (63) | 64.05 ± 11.55 (64.5) | 61.91 ± 12.77 (63) | 0.24 |
Sex | ||||
Male | 84 (24.6) | 12 (21.4) | 72 (25.3) | 0.63 |
Female | 257 (75.4) | 44 (78.6) | 213 (74.7) | |
Main language*: | ||||
Hebrew | 243 (73.4) | 47 (85.5) | 196 (71.0) | Hebrew vs. non-Hebrew |
Arabic | 32 (9.7) | 3 (5.5) | 29 (10.50) | |
Russian | 56 (16.9) | 5 (9.1) | P = 0.029 | |
Country of birth* | ||||
Israel | 157 (48.2) | 28 (52.8) | 129 (47.3) | Israeli-born vs. others |
Europe/America | 84 (25.8) | 13 (24.5) | 71 (26.0) | |
Asia/Africa | 30 (9.2) | 6 (11.3) | 24 (8.8) | P = 0.55 |
Former USSR | 55 (16.9) | 6 (11.3) | 49 (17.9) | |
Residence distance* | ||||
Haifa** | 134 (39.3) | 21 (37.5) | 113 (39.6) | 0.88 |
Suburbs** | 130 (38.1) | 21 (37.5) | 109 (38.2) | |
Periphery** | 77 (22.6) | 14 (25.0) | 63 (22.1) | |
Cancer sites* | ||||
Breast | 138 (41.8) | 24 (44.4%) | 114 (41.3%) | 0.76 |
Gynecological | 65 (19.7%) | 13 (24.1%) | 52 (18.8%) | 0.36 |
Gastrointestinal | 78 (23.6%) | 10 (18.5%) | 68 (24.6%) | 1.00 |
Prostate + urologic | 31 (9.4%) | 5 (9.3%) | 26 (9.4%) | 0.38 |
Lung | 18 (5.5%) | 2 (3.7%) | 16 (5.8%) | 0.74 |
Cancer recurrence* | ||||
Recurrent | 82 (24.0) | 19 (33.9) | 63 (22.1) | 0.062 |
Non-recurrent | 259 (76.0) | 37 (66.1) | 222 (77.9) | |
Evidence for advanced cancer* | ||||
Metastases | 159 (46.6) | 28 (50.0) | 131 (46.0) | 0.66 |
Non-metastatic | 182 (53.4) | 28 (50.0) | 154 (54.0) | |
Chemotherapy setting* | ||||
Neoadjuvant + adjuvant | 209 (65.7) | 34 (61.8) | 175 (66.5) | 0.53 |
Palliative + Curative | 109 (34.3) | 21 (38.2) | 88 (33.5) | |
Non-cancer related CM use* | ||||
Users | 165 (48.5) | 42 (75.0) | 123 (43.3) | <0.0001 |
Non-users | 175 (51.5) | 14 (25.0) | 161 (56.7) | |
Cancer-related CM use* | ||||
Users | 170 (50.1) | 39 (69.9) | 131 (46.3) | 0.002 |
Non-users | 169 (49.9) | 17 (30.4) | 152 (53.7) |